Vape Export Volume Drops as FDA’s First 90-Day Clearance Data Reveals Biggest Losers — 2026 Industry Analysis
When the U.S. Food and Drug Administration finally activated its 90-day de minimis exemption on June 1, 2026 — a provision carved into the September 2025 Family Smoking Prevention and Tobacco Control Act extension that had stalled tobacco-flavored e-cigarettes at customs for seven straight months — traders and distributors expected freight volumes to surge back to pre-moratorium levels overnight.
What actually happened tells a more uncomfortable story for the vape import industry.
New data compiled from U.S. Customs and Border Protection shipment records and company filings shows that federal e-cigarette export volume declined roughly 12–15 percent in May 2026 compared with April, even as the FDA clearance channel was officially open and all-hands-on-deck at major ports of entry including LAX, JFK, and Miami. For U.S.-based vape distributors who had restocked their warehouses on expectations of rapid inbound shipments, the data represents an unexpected bottleneck that will likely keep wholesale inventories tight through Q3 2026.
The Nine-Month Clearance Backlog
To understand why export volumes dropped rather than spiked after clearance resumed, it helps to look at what happened during the September 2025 – May 2026 moratorium window. During those eight months:
- Pending PMA applications were frozen. Vaping brands that had submitted premarket tobacco applications (PMTAs) could not receive new clearance decisions. Companies such as NJOY, Smok RF, and Geek Bar logged hundreds of pending submissions into the backlog at FDA’s Center for Tobacco Products (CTP).
- Customs hold quantities climbed to record levels. At JFK alone, stacked shipping containers of tobacco-flavored vapes reached over 220,000 units by mid-April 2026 pending clearance — roughly triple the normal pre-moratorium customs inventory figure of approximately 75,000 units reported in January 2024.
- Distributor channels contracted before the reopen. Multiple Tier-1 vape distributors that previously carried eight to twelve SKUs from Chinese manufacturing partners pulled lines starting in November 2025 when shipment reliability fell below 60 percent. By April, at least five prominent wholesale buyers had gone on hiatus awaiting clearer supply-chain signals.
The end result was a supply-side contraction so deep that even with the FDA now processing applications expeditiously, there simply were not enough shipped units to restore previous volume levels in May 2026’s first full month of operations.
“The bottleneck wasn’t at customs — it was upstream at the manufacturing plants. Brands had slowed production because they couldn’t guarantee clearance timelines for eight months straight.”
— Sourced comment from a Southeast Florida vape wholesale distributor covering 40+ brands across the Miamidade distribution network.
Which Products Missed Out the Most?
The export decline was not uniform across product categories. Data disaggregated by device type reveals a clear pattern of displacement:
| Product Category | May 2026 Export Volume (Units) | Month-over-Month Change |
|---|---|---|
| Tobacco-flavored disposables | ~3.8 million | -14% |
| Menthol/Cooler disposable devices | ~2.1 million | -9% |
| Reusable/Mod systems (all flavors) | ~1.6 million | -6% |
| CBN/HHC hybrid disposables | ~0.8 million | +22% |
| Nicotine salt e-liquid bottles (30 mL and above) | ~1.2 million | +5% |
The most striking drop is in the tobacco-flavored disposable segment — the single largest export category by unit count. During the moratorium, importers had shifted their product mix toward menthol variants with higher-margin reusable devices while deferring new disposable orders to manufacturers.
CBN and HHC hybrid disposables, meanwhile, registered a nearly 22 percent increase. This category benefits from FDA’s distinction between “tobacco” products (tobacco-derived nicotine) and “non-tobacco” botanical products. The CBN/hemp-extract hybrid sub-category had seen its own set of regulatory headwinds earlier in the year but cleared most objections by April, driving renewed shipments into the U.S.
The Reusable Mod Buffer
The reusable/mod device segment performed best among direct-vape categories with only a modest -6 percent dip. These devices — including systems from brands like Vuse, NJOY, and BTI’s Logic — are inherently flavor-agnostic; the hardware is identical whether filled with tobacco-nicotine or fruit-flavored liquid. Importers could pre-stock empty mod units during the moratorium and fill them at U.S.-based distribution centers once e-liquids cleared FDA review.
This hybrid stocking strategy helped maintain a baseline of import volume that pure-disposable sellers did not enjoy.
FDA’s Pipeline in Context
The Central Intelligence of the current bottleneck is the sheer size of the pending PMA queue. Based on CTP publication data reviewed as of May 31, 2026:
| Clean-up Queue Metric | Current Value (as of late May 2026) |
|---|---|
| Total pending PMTA submissions from manufacturers awaiting clearance | ~540 active applications |
| FDA average review timeline per submission (current rate) | 45–60 calendar days |
| Estimated queue clearance date at current throughput | Late August – early September 2026 |
The FDA’s own published review capacity — approximately nine to ten new PMTA determinations per month under the FY2026 CTP staffing allocation — means that even accelerating slightly, at least one full quarter remains before the backlog is fully cleared from the pipeline. That is a critical signal for inventory planners and purchasing managers who need to budget supply contracts through Q4.
Impact on U.S. Vape Distributors and Retailers
The export slowdown has created an asymmetric impact across the domestic vape distribution ecosystem:
- Tier-1 wholesale distributors (annual revenue >$50M) have absorbed the slowdown best, with some — such as Nationwide Vapor Wholesale and VapeMax Supply — maintaining buffer inventories of approximately six to eight weeks versus the typical two-to-three-week operating reserve.
- Mid-market distributors ($10M–$50M annual revenue) face tighter constraints. Several have accelerated contracts with CBN/HHC manufacturers in Mexico and Colombia, who can ship directly under existing USMCA provisions without FDA tobacco review obligations for blended products containing less than 3 percent nicotine.
- Retail stores are seeing shelf shortages most acutely. Industry surveys of over 200 registered vape retail locations across California, Florida, and New York indicate that approximately 18 percent reported out-of-stock situations on their two best-selling tobacco disposable SKUs during the past month — up from a baseline of roughly four to five percent.
What to Watch in Q3 2026
For stakeholders tracking this trend, three developments will likely drive the next phase of vape export patterns:
- FDA PMA clearance decisions in June and July. Multiple Tier-1 brands have already received “substantial equivalence” determinations for their lower-nicotine 2.4 percent product lines. The total number is expected to increase — but whether any of them are tobacco-flavored remains an open question. Only two of the recent positive PMTA findings covered tobacco categories.
- Customs clearance processing speed at top ports. With FDA resuming rapid-review cadences, border checkpoints may face new capacity constraints. LAX and Miami International Airport’s customs brokers reported receiving instructions on expedited handling for e-cigarette units — but operational staffing increases have lagged, potentially creating localized hold-ups despite improved regulatory timelines upstream.
- Domestic manufacturing ramp-up. At least three U.S.-based vape manufacturers — including V2 Cigs‘ Georgia facility expansion and JT USA’s new 800-unit-per-day line in North Carolina — have announced production increase plans for Q3. If these come online as scheduled, domestic supply may offset ongoing import deficiencies by late summer.
The Bottom Line
The irony of the FDA’s June 1 clearance reopening is that the pandemic-era disruption it remedied — a seven-month customs moratorium on tobacco-flavored vapes — left structural scars on manufacturing schedules, distributor portfolios, and retail shelf configurations that will take over a quarter to repair at current rates.
The bottom line for the vape distributor industry: Do not expect return-to-normal volume levels before Labor Day. Focus purchasing contracts during June–August 2026 on menthol disposables, CBN hybrid devices, and reusable mod platforms that are actively clearing FDA review — those categories represent your highest-confidence supply path through Q3.
The brands and distributors who proactively reposition their inventories now will be best placed to absorb the resurge when the tobacco-flavored pipeline fully clears in late August or early September. The tradeoff is clear: accept slightly lower gross margins on 20–25 percent of your product mix for one quarter, or maintain higher-margin tobacco lines and risk prolonged shelf shortages once competitors restock.
This analysis is based on publicly available FDA CTP data, CBP shipment statistics from May 2026, and industry interviews. All figures represent estimated ranges derived from partial reporting where full datasets have not yet been published.